1-乙基-1,2,3,6-四氢-4-吡啶羧酸 | 701905-55-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-乙基-1,2,3,6-四氢-4-吡啶羧酸
• 英文名称: 1-Ethyl-1,2,3,6-tetrahydropyridine-4-carboxylic acid
• 英文别名: 1-ethyl-3,6-dihydro-2H-pyridine-4-carboxylic acid
• CAS: 701905-55-7
• 化学式: C₈H₁₃NO₂
• 分子量: 155.19
• InChiKey: ARIVUPAODXJENP-UHFFFAOYSA-N

物化性质

• 沸点：
  280.9±35.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
  申请人：LegoChem Biosciences, Inc.

  公开号：US10961242B2

  公开（公告）日：2021-03-30

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

  本发明涉及作为自体毒素抑制剂的新型化合物，用于治疗和预防由自体毒素激活或溶血磷脂酸浓度升高引起的病症或紊乱，以及含有本发明的药物组合物。 本发明的新型化合物是自体毒素抑制剂，通过抑制溶血磷脂酸的产生，可用于治疗或预防心血管疾病、癌症、代谢紊乱、肾脏疾病、肝脏疾病、炎症性疾病、神经系统疾病、呼吸系统疾病、纤维化疾病、眼部疾病、胆汁淤积性和其他形式的慢性瘙痒症，或急性或慢性器官移植排斥反应。
• Sulfamide derivatives and preparation method and use thereof
  申请人：HitGen Ltd.

  公开号：US11149008B2

  公开（公告）日：2021-10-19

  The present invention discloses a compound shown in formula I or a stereoisomer, pharmaceutically acceptable salt, crystal form, solvate or isotopologue thereof. The compound of the present invention shows excellent inhibition activity against histone deacetylases, has remarkable inhibition effects on cancer cells, and provides a new choice of drugs used for the clinic treatment and diseases related to the abnormal activity of histone deacetylases.

  本发明公开了一种式 I 所示的化合物或其立体异构体、药学上可接受的盐、晶型、溶液或异构体。本发明的化合物对组蛋白去乙酰化酶有很好的抑制活性，对癌细胞有显著的抑制作用，为临床治疗与组蛋白去乙酰化酶活性异常有关的疾病提供了新的药物选择。
• SULFONAMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF
  申请人：Hitgen Inc.

  公开号：EP3398598B1

  公开（公告）日：2022-04-06
• SULFAMIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF
  申请人：HitGen Ltd.

  公开号：US20190031612A1

  公开（公告）日：2019-01-31

  The present invention discloses a compound shown in formula I or a stereoisomer, pharmaceutically acceptable salt, crystal form, solvate or isotopologue thereof. The compound of the present invention shows excellent inhibition activity against histone deacetylases, has remarkable inhibition effects on cancer cells, and provides a new choice of drugs used for the clinic treatment and diseases related to the abnormal activity of histone deacetylases.
• NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：LegoChem Biosciences, Inc.

  公开号：US20200172542A1

  公开（公告）日：2020-06-04

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.